IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
IPO Year: 1991
Exchange: NASDAQ
Website: idexx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2024 | $500.00 | Outperform | Leerink Partners |
| 7/25/2024 | $580.00 | Buy | BTIG Research |
| 1/30/2024 | $525.00 | Overweight → Neutral | Piper Sandler |
| 12/7/2023 | $602.00 | Outperform | Exane BNP Paribas |
| 12/4/2023 | Neutral → Buy | Cleveland Research | |
| 8/2/2023 | $610.00 | Overweight → Neutral | Atlantic Equities |
| 7/25/2022 | $415.00 | Buy → Hold | Stifel |
| 7/21/2022 | $530.00 → $435.00 | Neutral → Buy | Goldman |
| 7/12/2022 | $440.00 | Overweight | Piper Sandler |
| 5/5/2022 | $550.00 → $470.00 | Buy → Neutral | BofA Securities |
4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 second quarter financial results for Monday, August 4, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. EDT on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q2 2025 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen
The Catalyst® Cortisol Test provides veterinarians with real-time critical insights when evaluating dogs for Addison's disease and Cushing's syndrome WESTBROOK, Maine, June 5, 2025 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the launch of the Catalyst® Cortisol Test, which measures real-time quantitative cortisol concentrations to support the diagnosis of Addison's disease and diagnosis and management of Cushing's syndrome in dogs. IDEXX's Catalyst Cortisol Test is the third menu expansion in under a year for the Catalyst platform, further advancing the diagnostic capabilities available to veterinary practices at the p
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced that Andrew Emerson, Executive Vice President and Chief Financial Officer, and Tina Hunt, Executive Vice President, Global Strategy and Commercial, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 28, 2025 from 10:55 am – 11:25 am (EDT). A live audio webcast of the presentation will be available through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the presentation will be available via the same link. 2025 Investor Day IDEXX Laboratories, Inc. also announced today that it will host its 2025 Investor Day on Thursday,
Achieves first quarter revenue growth of 4% as reported and 5% organic, supported by CAG Diagnostics recurring revenue growth of 3% as reported and 4.5% organic. Organic revenue growth supported by benefits from IDEXX execution drivers, including continued solid new business gains and strong year-over-year global premium instrument installed base growth, including over 300 IDEXX inVue Dx™ placements. Delivers EPS of $2.96, an increase of 5% as reported and 7% on a comparable basis, supported by gross margin expansion of 90 basis points as reported and 80 basis points on a comparable basis. Adjusts 2025 revenue guidance to $4,095 million - $4,210 million, an increase of $40 million
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 first quarter financial results for Thursday, May 1, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q1 2025 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen to t
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February 27, 9:05 am – 9:45 am EST – Mike Erickson, PhD, Executive Vice President, and General Manager, Point of Care Diagnostics and Telemedicine, and Andrew Emerson, Senior Vice President, Corporate and CAG Finance, will participate in a fireside chat at the virtual BofA Securities Animal Health Summit. Monday, March 3, 11:35 am – 12:05 pm EST – Jay Mazelsky, President and Chief Executive Officer, will present at the 46th Annual Raymond James Institutional Investors Conference. Live webcasts of the presentations will be available through li
Achieves fourth quarter revenue growth of 6% as reported and on an organic basis, driven by CAG Diagnostics recurring revenue growth of 6% reported and 7% organic Solid growth supported by continued benefits from IDEXX execution drivers, including 9% year-over-year expansion of IDEXX's global premium instrument installed base and net customer gains across testing modalities Delivers fourth quarter EPS of $2.62, an increase of 13% as reported and 10% on a comparable basis driven by strong operating results Provides initial outlook for 2025 revenue of $4,055 million - $4,170 million, reflecting growth of 4% - 7% reported and 6% - 9% organic, supported by CAG Diagnostics recurring
Panel expansion planned over the next three years to cover the majority of canine cancer cases, transforming cancer detection and supporting earlier intervention WESTBROOK, Maine, Jan. 23, 2025 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the launch of IDEXX Cancer Dx™, a first-of-its-kind diagnostic panel with early detection of lymphoma in dogs, especially the 20 million dogs at higher risk* for cancer in North America.1 IDEXX Cancer Dx is an affordable and accessible blood test that can be added to panels for sick pets and integrated into annual wellness screenings for as low as $15, providing veterinarians in the U.
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 fourth quarter and full year financial results for Monday, February 3, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q4 2024 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telep
BOSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Sustainability Roundtable, Inc. (SR Inc), a leader in strategic advisory and support services, proudly announces the recipients of its 2024 Sustainable Business & Enterprise Roundtable (SBER) Awards. Presented the eve before its Summit for Sustainable Business VIII: Decarbonizing Corporate Global Operations at the St. Regis hotel in Washington, D.C., these recognitions commemorate SBER's 2024 standout sustainability leaders. Award Recipients and Achievements SR Inc is delighted to recognize the following SBER Member-Clients and Implementing Executives for their accomplishments in 2024. 1. Synopsys: Outstanding Corporate Leader Synopsys, Inc. (N
Leerink Partners initiated coverage of IDEXX Labs with a rating of Outperform and set a new price target of $500.00
BTIG Research initiated coverage of IDEXX Labs with a rating of Buy and set a new price target of $580.00
Piper Sandler downgraded IDEXX Labs from Overweight to Neutral and set a new price target of $525.00
Exane BNP Paribas initiated coverage of IDEXX Labs with a rating of Outperform and set a new price target of $602.00
Cleveland Research upgraded IDEXX Labs from Neutral to Buy
Atlantic Equities downgraded IDEXX Labs from Overweight to Neutral and set a new price target of $610.00
Stifel downgraded IDEXX Labs from Buy to Hold and set a new price target of $415.00
Goldman upgraded IDEXX Labs from Neutral to Buy and set a new price target of $435.00 from $530.00 previously
Piper Sandler initiated coverage of IDEXX Labs with a rating of Overweight and set a new price target of $440.00
BofA Securities downgraded IDEXX Labs from Buy to Neutral and set a new price target of $470.00 from $550.00 previously
SD - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
10-Q - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
DEF 14A - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
DEFA14A - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
PRE 14A - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
10-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)